Our Strategy

Coiled Therapeutics is making significant strides in oncology development, advancing AO-252, a first-in-class, brain-penetrant small molecule targeting a previously undruggable protein in precision oncology. This orally bioavailable therapy is designed to address critical unmet needs in hard-to-treat solid tumours, including brain metastases – a challenging area with limited targeted treatment options. With encouraging early clinical data showcasing meaningful tumour shrinkage alongside a benign safety profile, AO-252 offers the potential to significantly improve patient care within a market comparable ($20 billion) to the established success of PARP, CDK, and AR inhibitors. Our strategy focuses on translating this innovative science into substantial therapeutic value and shareholder returns.

A $20 billion addressable market comparable to PARP, CDK, and AR inhibitors.

Our commercialisation approach is centred on a clear, value-creation pathway designed to attract leading global biotech and pharmaceutical partners. We are focused on generating robust clinical data from our ongoing Phase 1 trials, particularly in prostate cancer, with key readouts expected by the end of 2026. These comprehensive data packages will underscore AO-252's therapeutic and commercial potential, facilitating strategic co-development, licensing, or acquisition discussions with major pharmaceutical and biotech companies. The recent $3.05 billion acquisition of Halda Therapeutics by Johnson & Johnson, involving a similar-stage prostate cancer asset, highlights the active M&A landscape and validates the significant valuation potential for innovative therapies in this sector.

Key clinical readouts expected by end of 2026 — pivotal inflection points for value creation.

Operating with a capital-efficient development model and led by an experienced team with a proven track record in drug development and market navigation, Coiled Therapeutics is well-positioned for growth. Our near-term goal is to generate pivotal data by the end of 2026, which will act as critical inflection points that will de-risk the asset and unlock considerable shareholder value. By pursuing flexible commercialisation strategies that prioritise strategic partnerships, we aim to accelerate AO-252's journey from clinical promise to patient impact, ensuring optimal returns for our investors while advancing a truly innovative targeted cancer therapy.